Physiologically Based Pharmacokinetic Modeling to Unravel the Drug-gene Interactions of Venlafaxine: Based on Activity Score-dependent Metabolism by CYP2D6 and CYP2C19 Polymorphisms-Reference-Cited by-同舟云学术

Physiologically Based Pharmacokinetic Modeling to Unravel the Drug-gene Interactions of Venlafaxine: Based on Activity Score-dependent Metabolism by CYP2D6 and CYP2C19 Polymorphisms

Published:2024-03-05 Issue:4 Volume:41 Page:731-749
ISSN:0724-8741
Container-title:Pharmaceutical Research
language:en
Short-container-title:Pharm Res

Author:

Shen Chaozhuang,Yang Hongyi,Shao Wenxin,Zheng Liang,Zhang Wei,Xie Haitang,Jiang Xuehua,Wang Ling^ORCID

Funder

Key Research and Development Program of Science and Technology Department of the Sichuan Province 111 Project

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s11095-024-03680-8.pdf

Reference57 articles.

1. Marwaha S, Palmer E, Suppes T, Cons E, Young AH, Upthegrove R. Novel and emerging treatments for major depression. Lancet. 2023;401(10371):141–53.

2. FDA. Lable-EFFEXOR XR® (venlafaxine extended-release) capsules 2023 [Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/020699s118lbl.pdf.

3. Zhou Q, Li X, Yang D, Xiong C, Xiong Z. A comprehensive review and meta-analysis of neurological side effects related to second-generation antidepressants in individuals with major depressive disorder. Behav Brain Res. 2023;447:114431.

4. Fogelman SM, Schmider J, Venkatakrishnan K, von Moltke LL, Harmatz JS, Shader RI, et al. O- and N-demethylation of venlafaxine in vitro by human liver microsomes and by microsomes from cDNA-transfected cells: effect of metabolic inhibitors and SSRI antidepressants. Neuropsychopharmacology. 1999;20(5):480–90.

5. Liebowitz MR, Tourian KA. Efficacy, safety, and tolerability of desvenlafaxine 50 mg/d for the treatment of major depressive disorder:a systematic review of clinical trials. Prim Care Companion J Clin Psychiatry. 2010;12(3):PCC.09r00845.